Monitor the company's proxy statement and 10-K for details on the proposed share increase in the stock incentive plan, as this could impact future dilution. The outcome of these votes is expected to be routine with management recommendations likely to pass.
Price Chart
Executive Summary
BioCryst Pharmaceuticals is holding its 2026 annual meeting to vote on several proposals, including the election of three directors, ratification of auditors, an advisory vote on executive compensation, and approval of an amended stock incentive plan to increase shares available for issuance. This is a routine annual shareholder meeting with no activist involvement or contested issues.
Key Facts
- Annual meeting scheduled for June 11, 2026
- Three director nominees: Theresa M. Heggie, Amy E. McKee, M.D., and Jon P. Stonehouse
- Proposal to ratify Ernst & Young LLP as independent auditors
- Advisory vote on executive compensation
- Proposal to amend and restated Stock Incentive Plan to increase shares available for issuance
Financial Impact
Approval of the amended Stock Incentive Plan would increase dilution potential, but no specific share count or financial impact is disclosed in this filing
Risk Factors
- Potential dilution from approval of additional shares in the stock incentive plan
- Shareholder opposition to executive compensation if deemed excessive
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-016373 |
| Document: 0001140361-26-016373-index-headers.html | 0001140361-26-016373 |
| Document: 0001140361-26-016373-index.html | 0001140361-26-016373 |
| Document: 0001140361-26-016373.txt | 0001140361-26-016373 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $9.07 $10.17 | ▲ +12.13% | ▲ +12.73% | $8.17 (−9.92%) |
Jun 29, 2026 13w ago | 8-K | $9.55 $9.34 | ▼ −2.20% | ▼ −1.92% | $8.17 (−14.45%) |
Jun 12, 2026 16w ago | 8-K | $9.06 $9.91 | ▲ +9.38% | ▲ +10.13% | $8.17 (−9.82%) |
Jun 12, 2026 16w ago | Press Release | $8.70 $10.45 | ▲ +20.11% | ▲ +18.34% | $8.17 (−6.09%) |
May 19, 2026 19w ago | Insider Cluster | $8.74 $8.99 | ▲ +2.86% | ▲ +2.12% | $8.17 (−6.52%) |
May 13, 2026 20w ago | 144 | $9.60 $8.50 | ▼ −11.46% | ▼ −10.85% | $8.17 (−14.90%) |
May 6, 2026 21w ago | 8-K | $8.83 $8.25 | ▼ −6.57% | ▼ −9.35% | $8.17 (−7.47%) |
May 4, 2026 21w ago | 8-K | $9.20 $8.57 | ▼ −6.85% | ▼ −12.49% | $8.17 (−11.20%) |
Apr 23, 2026 23w ago | DEFA14A | $8.94 $8.37 | ▼ −6.38% | ▼ −10.40% | $8.17 (−8.61%) |
Apr 15, 2026 24w ago | Press Release | $9.44 $8.80 | ▼ −6.78% | ▼ −12.82% | $8.17 (−13.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access